Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Latest in bladder cancer from the second half of 2025

ESMO 2025

Published: 25 Nov 2025

Views: 2451

Rating:

Save

Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Enrique Grande

Dr Alison Birtle (Lancashire Teaching Hospitals, UK), Dr Ignacio Durán (Marques de Valdecilla University Hospital, Spain), Prof Evanguelos Xylinas (Bichat-Claude Bernard Hospital, France), Dr Giuseppe Simone (Regina Elena National Cancer Institute, Italy) and Dr Enrique Grande (University Hospital Quironsalud Madrid, Madrid, Spain) discuss the latest updates in bladder cancer treatment for the second half of 2025.

	Thinking outside the box: Novel or unexpected data
	Latest in NMIBC
	Advanced disease in bladder cancer
	Updates in the perioperative setting
	Take home messages

Related Videos

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer

Dr Jianbo Wang - MD Anderson Cancer Center, Houston, USA

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer ( Dr Jianbo Wang - MD Anderson Cancer Center, Houston, USA )

Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer

Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA

Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer ( Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )

HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma

Dr Sapna Patel - University of Colorado Anschutz, Aurora, USA

PRAME-targeted TCR therapy shows high response rates in metastatic uveal melanoma ( Dr Sapna Patel - University of Colorado Anschutz, Aurora, USA )

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich

Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )

Bladder cancer updates from the first half of 2025

Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Benjamin Pradere

Bladder cancer updates from the first half of 2025 ( Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Benjamin Pradere )

Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada

Darolutamide plus ADT provides deep and durable PSA responses in metastatic hormone-sensitive prostate cancer ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )

EAU 2025: Updates in NMIBC

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Alexandra Masson-Lecomte and Dr Giuseppe Simone

EAU 2025: Updates in NMIBC ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Alexandra Masson-Lecomte and Dr Giuseppe Simone )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

More from ecancer